CN104583238A - 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法 - Google Patents

用于产生具有物种间、靶标内交叉反应性之抗体分子的方法 Download PDF

Info

Publication number
CN104583238A
CN104583238A CN201380044710.8A CN201380044710A CN104583238A CN 104583238 A CN104583238 A CN 104583238A CN 201380044710 A CN201380044710 A CN 201380044710A CN 104583238 A CN104583238 A CN 104583238A
Authority
CN
China
Prior art keywords
species
antibody
il22r
reactivity
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380044710.8A
Other languages
English (en)
Chinese (zh)
Inventor
约翰内斯·约斯夫·威廉默斯·德哈德
克里斯托夫·弗雷德里克·杰罗姆·布朗什托
塞巴斯蒂安·保罗·万德沃宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX SE
Original Assignee
ArgenX SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX SE filed Critical ArgenX SE
Publication of CN104583238A publication Critical patent/CN104583238A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380044710.8A 2012-08-31 2013-08-30 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法 Pending CN104583238A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
US61/695,664 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (1)

Publication Number Publication Date
CN104583238A true CN104583238A (zh) 2015-04-29

Family

ID=49080903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380044710.8A Pending CN104583238A (zh) 2012-08-31 2013-08-30 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法

Country Status (10)

Country Link
US (1) US20150203840A1 (enExample)
EP (2) EP2890711B1 (enExample)
JP (1) JP6391574B2 (enExample)
CN (1) CN104583238A (enExample)
AU (2) AU2013310924B2 (enExample)
CA (1) CA2878712A1 (enExample)
DK (1) DK2890711T3 (enExample)
IL (1) IL236523B (enExample)
IN (1) IN2015DN00140A (enExample)
WO (1) WO2014033252A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828753C (en) 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
CN105658666B (zh) 2013-08-01 2021-07-27 鲁汶大学 抗garp蛋白及其用途
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
MX2020004512A (es) 2017-10-31 2020-08-13 Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
EP3723803A4 (en) 2017-12-12 2021-09-15 Pionyr Immunotherapeutics, Inc. ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP4277706A1 (en) 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735629A (zh) * 2002-11-08 2006-02-15 埃博灵克斯股份有限公司 针对肿瘤坏死因子－α的单结构域抗体及其用途
CN1798768A (zh) * 2003-03-24 2006-07-05 津莫吉尼蒂克斯公司 抗il－22ra抗体和结合伴侣以及在炎症中的使用方法
CN101426816A (zh) * 2006-02-21 2009-05-06 惠氏公司 抗人白介素22的抗体及其用途
WO2011069104A2 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
CN102216328A (zh) * 2008-07-02 2011-10-12 阿尔金-X公司 骆驼科动物来源的抗原结合多肽
US20110311449A1 (en) * 2010-02-10 2011-12-22 Affitech Research As Antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531812T1 (de) * 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2004223836A1 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-IL-20 antibodies and binding partners and methods of using in inflammation
RU2518295C2 (ru) * 2005-06-21 2014-06-10 Ксома Текнолоджи Лтд. IL-1бета-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ФРАГМЕНТЫ
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
DK2643019T3 (en) * 2010-11-24 2019-04-15 Lexicon Pharmaceuticals Inc ANTIBODIES AGAINST NOTE PECTINACETYL ESTERASE

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735629A (zh) * 2002-11-08 2006-02-15 埃博灵克斯股份有限公司 针对肿瘤坏死因子－α的单结构域抗体及其用途
CN1798768A (zh) * 2003-03-24 2006-07-05 津莫吉尼蒂克斯公司 抗il－22ra抗体和结合伴侣以及在炎症中的使用方法
CN101426816A (zh) * 2006-02-21 2009-05-06 惠氏公司 抗人白介素22的抗体及其用途
CN102216328A (zh) * 2008-07-02 2011-10-12 阿尔金-X公司 骆驼科动物来源的抗原结合多肽
WO2011069104A2 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
WO2011069104A3 (en) * 2009-12-04 2011-08-04 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US20110311449A1 (en) * 2010-02-10 2011-12-22 Affitech Research As Antibodies

Also Published As

Publication number Publication date
AU2017204188A1 (en) 2017-07-13
EP2890711A1 (en) 2015-07-08
IL236523A0 (en) 2015-02-26
JP6391574B2 (ja) 2018-09-26
AU2013310924A1 (en) 2015-01-29
DK2890711T3 (en) 2017-02-27
AU2013310924B2 (en) 2017-08-03
EP2890711B1 (en) 2017-01-04
IL236523B (en) 2018-12-31
US20150203840A1 (en) 2015-07-23
EP2977386A1 (en) 2016-01-27
JP2015530087A (ja) 2015-10-15
WO2014033252A1 (en) 2014-03-06
CA2878712A1 (en) 2014-03-06
AU2013310924A8 (en) 2015-04-30
IN2015DN00140A (enExample) 2015-06-12

Similar Documents

Publication Publication Date Title
CN104583238A (zh) 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法
US11629434B2 (en) Antibody screening methods
JP7001474B2 (ja) 非免疫原性単一ドメイン抗体
US12442106B2 (en) Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution
JP2023113686A (ja) ｐＨ依存的抗体の調製方法
JP7171737B2 (ja) Ｓｆｔｓｖに結合可能なナノ抗体及びその使用
JP2020535799A5 (enExample)
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
CN107739405A (zh) 骆驼科动物来源的抗原结合多肽
US20200369774A1 (en) Il-6r antibody and antigen binding fragment thereof and medical use
US9090994B2 (en) Antibody humanization by framework assembly
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
CN103588876B (zh) 一种生产人源化抗体或抗原结合片段的方法
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
WO2021105669A1 (en) Antibodies
Houimel The analysis of VH and VL genes repertoires of Fab library built from peripheral B cells of human rabies virus vaccinated donors
US20090155850A1 (en) Horse:Human Chimeric Antibodies
TW202413405A (zh) 抗體、其抗原結合片段及其藥物用途
HK40047350A (en) Antibody screening methods
HK40047350B (en) Antibody screening methods
CN118240087A (zh) 一种Anti-RNAse R抗体及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Holland Breda

Applicant after: Alkings Co.

Address before: Holland Breda

Applicant before: ARGEN-X B.V.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20180122

Address after: Belgium zwijnaarde

Applicant after: ARGEN-X B.V.

Address before: Holland Breda

Applicant before: Alkings Co.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150429

WD01 Invention patent application deemed withdrawn after publication